

**Text Version** 

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services Journals Database MeSH Database Single Citation Matcher **Batch Citation Matcher** Clinical Queries LinkOut Cubby

Related Resources **Order Documents NLM Gateway TOXNET** Consumer Health Clinical Alerts ClinicalTrials.gov **PubMed Central** 

**Privacy Policy** 

□ 1: Int J Cancer. 2001 Nov15;94(4):480-4.

Related Articles, Links

InterS@ience


C-MYC and IGF-II mRNA-binding protein (CRD-BP/IMP-1) in benign and malignant mesenchymal tumors.

Ioannidis P, Trangas T, Dimitriadis E, Samiotaki M, Kyriazoglou I, Tsiapalis CM, Kittas C, Agnantis N, Nielsen FC, Nielsen J, Christiansen J, Pandis N.

Department of Genetics, St. Savas Hospital, Athens, Greece.

Mouse coding region determinant-binding (mCRD-BP) and human IGF-II mRNA-binding 1 (hIMP-1) proteins are orthologous mRNAbinding proteins that recognize c-myc and IGF-II mRNA, respectively, and regulate their expression posttranscriptionally. Here, we confirm that human CRD-BP/IMP-1 binds to c-myc mRNA and that it is predominantly expressed in fetal tissues. Moreover, hCRD-BP/IMP-1 expression was detected in cell lines of neoplastic origin and in selected primary tumors. In a series of 33 malignant and 10 benign mesenchymal tumors, 73% and 40%, respectively, were found to express hCRD-BP/IMP-1. In particular, expression was significant in 14 Ewing's sarcomas, all of which were positive. The data suggest that hCRD-BP/IMP-1 plays a role in abnormal cell proliferation in mesenchymal tumors. Copyright 2001 Wiley-Liss, Inc.

PMID: 11745432 [PubMed - indexed for MEDLINE]



Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Freedom of Information Act | Disclaimer

Aug 6 2003 12:56:11